WEREWOLF THERAPEUTICS, INC. Stock-Based Compensation
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Stock-Based Compensation of $1.35 million for the 6-month period ending 2026-06-30, per its S-4 filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-22
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $419.00K, a 76.63% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $929.00K, a 53.69% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.21M, a 36.43% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.23M, a 38.69% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $8.01M, a 8.22% increase from fiscal 2022.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $7.40M, a 80.71% increase from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2021 was $4.09M, a 547.94% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2020 was $632.00K.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $419.00K derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $1.35M S-4 · filed 2026-09-22 | $2.56M derived: sum of 3 quarters · filed 2026-09-22 | $3.79M derived: sum of 4 quarters · filed 2026-09-22 |
| 2026-03-31 | $929.00K 10-Q · filed 2026-05-07 | $2.14M derived: sum of 2 quarters · filed 2026-09-22 | $3.38M derived: sum of 3 quarters · filed 2026-09-22 | $5.17M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $1.21M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $2.45M derived: sum of 2 quarters · filed 2026-09-22 | $4.24M derived: sum of 3 quarters · filed 2026-09-22 | $6.25M S-4 · filed 2026-09-22 |
| 2025-09-30 | $1.23M derived: 10-Q 9 month − S-4 6 month · filed 2025-11-04 | $3.03M derived: sum of 2 quarters · filed 2026-09-22 | $5.03M 10-Q · filed 2025-11-04 | $6.94M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $1.79M derived: S-4 6 month − 10-Q 3 month · filed 2026-09-22 | $3.80M S-4 · filed 2026-09-22 | $5.71M derived: sum of 3 quarters · filed 2026-09-22 | $7.72M derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-03-31 | $2.01M 10-Q · filed 2026-05-07 | $3.91M derived: sum of 2 quarters · filed 2026-09-22 | $5.92M derived: sum of 3 quarters · filed 2026-09-22 | $8.53M derived: sum of 4 quarters · filed 2026-09-22 |
| 2024-12-31 | $1.91M derived: S-4 12 month − 10-Q 9 month · filed 2026-09-22 | $3.92M derived: sum of 2 quarters · filed 2026-09-22 | $6.52M derived: sum of 3 quarters · filed 2026-09-22 | $8.83M S-4 · filed 2026-09-22 |
| 2024-09-30 | $2.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $4.61M derived: sum of 2 quarters · filed 2025-11-04 | $6.92M 10-Q · filed 2025-11-04 | $8.79M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $2.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $4.91M 10-Q · filed 2025-08-14 | $6.78M derived: sum of 3 quarters · filed 2025-08-14 | $8.88M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.31M 10-Q · filed 2025-05-08 | $4.18M derived: sum of 2 quarters · filed 2025-05-08 | $6.28M derived: sum of 3 quarters · filed 2025-05-08 | $8.21M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $3.97M derived: sum of 2 quarters · filed 2025-03-11 | $5.90M derived: sum of 3 quarters · filed 2025-03-11 | $8.01M 10-K · filed 2025-03-11 |
| 2023-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $4.03M derived: sum of 2 quarters · filed 2024-11-07 | $6.13M 10-Q · filed 2024-11-07 | $8.08M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.04M 10-Q · filed 2024-08-08 | $5.98M derived: sum of 3 quarters · filed 2024-08-08 | $7.92M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.11M 10-Q · filed 2024-05-03 | $4.05M derived: sum of 2 quarters · filed 2024-05-03 | $5.99M derived: sum of 3 quarters · filed 2024-05-03 | $7.76M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $3.88M derived: sum of 2 quarters · filed 2024-03-07 | $5.66M derived: sum of 3 quarters · filed 2024-03-07 | $7.40M 10-K · filed 2024-03-07 |
| 2022-09-30 | $1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.71M derived: sum of 2 quarters · filed 2023-11-14 | $5.46M 10-Q · filed 2023-11-14 | $6.75M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.52M 10-Q · filed 2023-08-10 | $4.82M derived: sum of 3 quarters · filed 2023-08-10 | $6.30M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.75M 10-Q · filed 2023-05-11 | $3.04M derived: sum of 2 quarters · filed 2023-05-11 | $4.52M derived: sum of 3 quarters · filed 2023-05-11 | $5.30M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $2.77M derived: sum of 2 quarters · filed 2023-03-23 | $3.56M derived: sum of 3 quarters · filed 2023-03-23 | $4.09M 10-K · filed 2023-03-23 |
| 2021-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.26M derived: sum of 2 quarters · filed 2022-11-10 | $2.80M 10-Q · filed 2022-11-10 | $3.02M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $781.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.32M 10-Q · filed 2022-08-11 | $1.54M derived: sum of 3 quarters · filed 2022-08-11 | $1.67M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $539.00K 10-Q · filed 2022-05-10 | $760.00K derived: sum of 2 quarters · filed 2022-05-10 | $893.00K derived: sum of 3 quarters · filed 2022-05-10 | $1.11M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $221.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $354.00K derived: sum of 2 quarters · filed 2022-03-24 | $575.00K derived: sum of 3 quarters · filed 2022-03-24 | $632.00K 10-K · filed 2022-03-24 |
| 2020-09-30 | $133.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $354.00K derived: sum of 2 quarters · filed 2021-11-10 | $411.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $221.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $278.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $57.00K 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |